Take a deep dive into the ASEAN biopharmaceutical landscape, and see why and how Chinese biopharma companies on the cusp of internationalization are prioritising their ASEAN market entry and investment strategy.
The emerging economies in ASEANpresent an attractive market opportunity in view of the rising demand for healthcare driven by an ageing population and an increase in the prevalence of chronic diseases. However, obstacles abound for effectively penetrating ASEAN markets, including the lack of harmonisation of guidelines, economic diversity, language barriers, and uneven distribution of wealth.
In this whitepaper, ASK Health (part of Access Health International, an international think tank with a mission to improve access to high quality and affordable healthcare) studied the global market expansion of Chinese biopharma companies, particularly with regard to their expanding footprint in the ASEAN region. The whitepaper explores critical components of the trend of greater collaboration between Chinese biopharma and ASEAN, including the region’s biopharmaceutical market landscape, the regulatory environment in ASEAN countries, and how Chinese biopharma companies are responding to this emerging opportunity.
